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Abstract
The heart has traditionally been considered a radio-resistant organ that would be unaffected by
cardiac doses below about 30 Gray. During the last few years, however, evidence that radiation-
related heart disease can occur following lower doses has emerged from several sources. These
include studies of breast cancer patients, who received mean cardiac doses of 3–17 Gray when
given radiotherapy following surgery, and studies of survivors of the atomic bombings of Japan
who received doses of up to 4 Gray.
At doses above 30 Gray, radiation-related heart disease may occur within a year or two of
exposure and risk increases with higher radiotherapy dose, younger age at irradiation, and the
presence of conventional risk factors. At lower doses the typical latent period is much longer and
is often more than a decade. However, the nature and magnitude of the risk following lower doses
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is not well characterized, and it is not yet clear whether there is a threshold dose below which
there is no risk.
The evidence regarding radiation-related heart disease comes from several different disciplines.
The present review brings together information from pathology, radiobiology, cardiology,
radiation oncology and epidemiology. It summarises current knowledge, identifies gaps in that
knowledge, and outlines some potential strategies for filling them. Further knowledge about the
nature and magnitude of radiation-related heart disease would have immediate application in
radiation oncology. It would also provide a basis for radiation protection policies for use in
diagnostic radiology and occupational exposure.
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INTRODUCTION
It has been recognized since the 1960s that the heart may be damaged by substantial doses
of radiation [>30 Gray (Gy)], such as used to occur during mantle radiotherapy for Hodgkin
lymphoma. During the last few years, however, evidence that radiation-related heart disease
(RRHD) can occur following doses below 20 Gy has emerged from several independent
sources. Those sources include studies of breast cancer patients who received mean cardiac
doses of 3 to 17 Gy when given radiotherapy following surgery and studies of survivors of
the atomic bombings of Japan who received doses of up to 4 Gy.
At doses above 30 Gy, an increased risk of RRHD can becomes apparent within a year or
two of exposure, and the risk increases with higher radiotherapy dose, younger age at
irradiation, and the presence of conventional risk factors. At lower doses, the typical latency
period is much longer and is often more than a decade. The nature and magnitude of the risk
following lower doses is not well characterized, and it is not yet clear whether there is a
threshold dose below which there is no risk.
The evidence regarding RRHD comes from several different disciplines. The present review
brings together information from pathology, radiobiology, cardiology, radiation oncology,
and epidemiology; it summarizes current knowledge, identifies gaps in that knowledge, and
outlines some potential strategies for filling them.
CURRENT KNOWLEDGE
Pathology
The pathological expressions of RRHD documented following therapeutic irradiation can be
broadly reduced to four conditions: pericarditis, pericardial fibrosis, diffuse myocardial
fibrosis, and coronary artery disease (CAD) 1 and 2. Radiation may also cause valvular
disease, although the evidence for this is not as strong. None of these conditions is specific
to radiation.
Radiation-related pericarditis is characterized by an exudate of a variable amount of protein-
rich fluid within the pericardial sac (pericardial effusion). Rapid accumulation of this fluid
can, in rare cases, cause potentially fatal cardiac tamponade. Almost invariably, fibrin
accumulates on the mesothelial lining of the epicardium or the parietal pericardium.
Pericardial fibrosis consists of collagen deposition, usually in the parietal pericardium,
replacing the peripheral adipose layer and increasing the thickness of the fibrous layer
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(normally, < 0.5 mm) to as much as 8 mm. This results in a rigid pericardial sac (Fig. 1) that
may produce constriction and is often accompanied by effusion. Fibrin also accumulates
interstitially in the thickened pericardium (1). accompanied by effusion. Fibrin also
accumulates interstitially in the thickened pericardium (1).
As the name implies, diffuse myocardial fibrosis consists of diffuse proliferation of bands of
collagen separating and/or replacing myocytes (Fig. 2). It occurs in patches, often in the
anterior wall of the left ventricle. Experimental studies have demonstrated that this condition
results from damage to the endothelium of the myocardial blood capillaries and can lead to
ischemia and ultimately fibrosis (3). If it is extensive, myocardial fibrosis may lead to
congestive heart failure. The morphology of radiation-related CAD is essentially the same as
CAD resulting from atherosclerosis from other causes: intimal proliferation of
myofibroblasts, with lipid-containing macrophages forming plaques that may fissure causing
thrombosis (4). This reduces the arterial lumen to various degrees (Fig. 3), resulting in the
clinical manifestations of ischemic heart disease: stable angina pectoris, unstable angina,
myocardial infarction (MI), and chronic ischemic heart disease. Endovascular irradiation
(used until recently to prevent coronary arterial restenosis postangioplasty) often causes
fibrosis of the adventitia in swine and probably also in humans. However, that feature is
often absent in CAD resulting from external irradiation. Valvular lesions characterized by
fibrosis and calcification have been described in irradiated patients (5).
Experimental Models
Pericardial, myocardial, and coronary artery lesions can all be reproduced by irradiating
appropriate animal models 1, 2 and 3, but direct experimental proof regarding radiation-
induced valvular disease is lacking at present. Experimental models commonly used to study
RRHD include rat, rabbit, and dog. Myocardial fibrosis and loss of cardiac function develop
several months after irradiation in all three species, although interstrain and interspecies
differences in expression 3, 6 and 7 mean that caution is required in extrapolating to
humans. Nevertheless, these animal models have provided insight into possible mechanisms
of RRHD.
Evidence from rodent models suggests that radiation can cause both microvascular and
macrovascular cardiac pathology. The microvascular pathology is characterized by a
decrease in capillary density, causing chronic myocardial ischemia and fibrosis.
Macrovascular disease occurs through an accelerated development of age-related
atherosclerosis.
Experiments investigating the effects of high-precision X-ray irradiation of the whole heart
in rats demonstrate that observable congestive heart failure develops in 100% of irradiated
animals within their normal lifespan following single doses of >15 Gy 2 and 8. At 10 Gy,
reduced capillary density has also been observed, but damage progression was slow, and
latency to clinical symptoms exceeded the normal life span of rats. Analysis of the effect of
varying dose fractionations on median latency to heart failure in experiments with up to 10
fractions yields alpha/beta ratios of <4 Gy (9). The low ratio suggests that the myocardium
behaves as a classical late-reacting tissue.
Studies of radiation-induced microvascular pathology in rats demonstrate focal loss of
alkaline phosphatase activity within a few weeks of heart irradiation. Loss of capillaries,
preceded by increased endothelial proliferation, occurs in enzyme-negative areas only (10).
Those foci start small and gradually increase in size, with a progressive decrease in local
capillary density. Histopathology at the time of heart failure demonstrates foci of ischemic
necrosis and reparative fibrosis unrelated to the distribution of major blood vessels.
Myocytes are terminally differentiated cells and are therefore relatively resistant to the direct
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cytotoxic effects of irradiation. Experimental evidence suggests that radiation-induced heart
failure is an effect of indirect myocyte toxicity secondary to microvascular damage and
ischemia. This is in contrast to anthracycline-induced heart failure, where anthracyclines are
known to be directly toxic to myocytes.
The pathogenesis of radiation-related atherosclerosis in large arteries has been studied in
ApoE−/− mice. These rodents spontaneously develop atherosclerotic plaques within 6 to 12
months, but radiation of vessels speeds this process due to local effects on the vascular
endothelium. The phenotype of the plaques is also altered by doses of ≥14 Gy, with an
increased frequency of intraplaque hemorrhage and inflammatory cells, so that they are
more vulnerable to rupture, causing thrombosis (11).
Based on these experimental findings, it is reasonable to formulate two hypotheses for the
biological mechanisms that lead to increased morbidity and mortality from coronary artery
disease after radiation exposure in humans. The first hypothesis is that radiation increases
the frequency of MI by interacting with the pathological pathway of age-related coronary
artery atherosclerosis, resulting in accelerated atherosclerosis in which disease is seen at a
younger age than would normally occur. The second hypothesis is that radiation increases
the lethality of age-related MI by reducing the heart’s tolerance to acute infarctions as a
result of microvascular damage to the myocardium. As shown in Fig. 4, these hypotheses are
not mutually exclusive, and the two mechanisms may act together to produce clinical heart
disease.
Animal models have also been used to test potential intervention strategies both before and
after local heart irradiation. Those strategies include use of methylprednisolone or ibuprofen
(12), captopril (13), amifostine (14), and a combination of pentoxifylline and alpha-
tocopherol (15). All agents showed some potential benefit in preventing morphologic or
functional deterioration experimentally, but their clinical usefulness has not yet been
demonstrated.
Clinical Manifestations and Management
A wide range of clinical cardiovascular problems can arise from radiation therapy (RT) for
thoracic malignancy. Radiation-related pericardial and myocardial diseases are less common
today than in the past, due to modifications in RT techniques, particularly for lymphomas
(16), resulting in lower radiation doses to the heart. The predominant clinical manifestation
of RRHD today is probably CAD, but the frequency with which it occurs is unknown, as it
does not differ clinically from CAD from other causes, and many radiation-related cases
may not be recognized as such.
Acute pericarditis is still occasionally seen within weeks after cardiac irradiation. Patients
present with pleuritic chest pain, fever, tachycardia, a pericardial rub, and characteristic
electrocardiographic abnormalities. Those signs and symptoms usually resolve quickly and
without consequence with nonsteroidal anti-inflammatory drug therapy. A proportion of
patients, however, develop chronic pericarditis up to 10 years later. The incidence of disease
is related to the volume of pericardium irradiated, the dose received, and possibly the
presence of effusion during the acute phase. The severity is variable, ranging from
asymptomatic pericardial thickening found incidentally to cardiac tamponade requiring
urgent pericardiocentesis. For those patients with recurrent effusion, some authorities
recommend subtotal pericardiectomy to prevent the development of severe constrictive
pericarditis, which can be difficult to treat effectively at a later stage (17).
Radiation-related myocardial fibrosis is often asymptomatic and is picked up only
incidentally on echocardiography more than 10 years after radiation therapy (18). Clinically
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significant ventricular dysfunction is uncommon but can occur, particularly in the context of
anthracycline chemotherapy and high radiation doses (>30 Gy) to large volumes of the
heart. The management of radiation-related cardiomyopathy currently follows guidelines for
the management of cardiac failure due to other causes.
Radiotherapy has been associated with valvular heart disease, which is common in some
series (18). The incidence has been related to mediastinal radiation doses of >30 Gy 19, 20
and 21 and younger age at irradiation 22, 23 and 24, with an average latency of >10 years
for asymptomatic and longer (median, 22 years) for symptomatic disease (20). Aortic
disease usually consists of mixed stenosis and regurgitation and is more common than mitral
and right-sided disease. Conduction system abnormalities have also been reported, often in
association with other types of RRHD. A variety of arrhythmias and conduction blocks have
been observed, but these are rarely clinically serious. Autonomic nervous system
dysfunction with a persistent nonvariable tachycardia has also been described (25).
Thoracic RT is now firmly established as a risk factor for CAD. Radiation-related CAD is
usually not detected until at least 10 years after exposure, and the magnitude of the risk with
modern RT techniques is not yet well defined. Relative risks increase with higher
radiotherapy doses 19 and 26, younger age at irradiation 23 and 26, and the presence of
conventional risk factors for coronary artery disease (20). Radiation-related CAD is
managed conventionally, with medical control of risk factors and percutaneous coronary
intervention or surgical bypass if indicated. Surgery may be technically challenging due to
the presence of mediastinal scarring, friability of the vessels, and a possible increased
restenosis rate of irradiated internal mammary vessels when they are chosen for coronary
artery bypass grafting (27). Patients most commonly presenting with RRHD are survivors of
breast cancer or HL, although RRHD has also been reported after radiotherapy for testicular
cancer (28) and peptic ulcer disease (29).
Studies of Patients with Hodgkin Lymphoma
In the general population, early changes indicative of atherosclerosis can be seen in young
adults, but clinical manifestations, such as angina and MI, rarely present until patients are at
least in their 50s. In contrast, young patients without conventional cardiac risk factors who
received mediastinal irradiation for HL can present with CAD in their 20s. In such
individuals the likely cause is clear, and they may provide an example of the hypothesis of
accelerated atherosclerosis referred to above.
In older people, among whom heart disease in the absence of radiotherapy is common,
RRHD is harder to identify, and much of our information about the risk comes from studies
in which a large population of HL patients treated with RT have been identified and
followed over many years. Information about heart disease is obtained either from patients’
medical records or from disease registers or death certificates, and the risk of developing or
dying from heart disease in the HL group can then be compared with that of the general
population or with another suitable control group.
A recent study of 1,474 5-year survivors treated for HL before age 40 found relative risk
(RR) values of 3 to 5 for cardiac morbidity of all types compared with the general
population, suggesting that 66 to 80% of all cardiac disease in the HL population was due to
therapy (30), while estimates of the RR of death from MI in HL patients compared with the
general population are in the range 2 to 9 31 and 32.
Both the radiotherapy techniques and the chemotherapy regimens used to treat HL are
evolving with time. Therefore, the impact of cardiac disease in HL survivors requires
periodic reevaluation. The modification of radiotherapy techniques has resulted in a
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reduction in the risk of death from some cardiac causes. For example, among 2,232 HL
patients treated at Stanford from 1960 to 1991, the RR for non-MI cardiac death fell from
5.3 to 1.4 when subcarinal blocking was introduced (26). However, the RR for fatal MI was
not changed significantly in this series, possibly due to continued RT exposure of the
proximal coronary arteries. Patients treated during the 1990s in Canada still had an increased
risk of hospitalization for cardiac disease that was more marked in those who received
combination therapy with anthracyclines (33), suggesting that an increased risk of late
cardiac effects had not yet been eliminated.
The proportional increase in the cardiac death rate is greater in survivors of childhood HL
than in adults. In a report from the U.S. Childhood Cancer Survivor Study (22), which
included 2,717 5-year survivors of childhood HL, the RR of death from all cardiac causes
compared with that of the general population was 11.9 (95% confidence interval [CI], 9.1–
15.3), while the RR of death from MI following mediastinal irradiation in childhood has
been estimated to be as high as 41.5 (95% CI, 18.1–82.1) with RT doses of ≥42 Gy (23).
Studies of Patients with Breast Cancer
In studies of patients with HL, the death rates from heart disease have, in the past, often
been so large that comparisons with rates in the general population gave a clear indication of
the magnitude of the risk. For breast cancer patients, cardiac doses from RT have been lower
and risks smaller. Therefore, the phenomenon of RRHD is less obvious in breast cancer
patients than in HL patients. In breast cancer, much of our knowledge of the effect of RT on
cardiovascular disease has come from long-term follow-up of women entered into trials in
which all women received similar treatment in terms of surgery and drugs, and then half of
the women were allocated at random also to receive adjuvant radiotherapy.
One of the first studies to examine the effect of RT on long-term survival in breast cancer
was published by Cuzick et al. in 1987 (34). This meta-analysis of randomized trials showed
that survival beyond 10 years was significantly worse for those receiving RT. This study
was unable to determine the disease responsible for the detrimental effect on survival, but
subsequent meta-analyses by the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) have shown that mortality from heart disease was increased by 27% (2p =
0.0001) in women randomized to surgery plus RT compared with women randomized to
surgery alone (35). Most of the increase was due to CAD. Aspects of the radiotherapy
techniques used in the earlier trials that contributed to the increased cardiac mortality
included field placement near the heart (particularly anterior fields used to treat the internal
mammary nodes), orthovoltage radiation that delivered high doses to the anterior part of the
heart, large daily fractions, and high total doses (36).
Recently, a preliminary analysis of updated EBCTCG data has related mortality from heart
disease to estimated cardiac doses in over 30,000 women followed for up to 20 years. There
is clear evidence that the radiation-related increase is higher in trials with larger mean
cardiac RT doses and that the risk of death from heart disease increases by 3% per Gy (95%
CI, 2%–5%; 2p < 0.00001) (37). That estimate can only be taken as an approximate
indication of the risk, as individual treatment plans were not available for the women in
those trials. Nevertheless, the data provide strong evidence that risk of RRHD was related to
cardiac dose in irradiated breast cancer patients.
Outside the context of a randomized trial, comparisons of mortality after various different
treatment regimens are often misleading because the prognosis of patients given different
treatments will vary (38). In breast cancer, however, a reliable indication of the effect of
radiotherapy on heart disease can be obtained by comparing the experience of irradiated
women with left-sided tumors with that of women with right-sided tumors (39). This can be
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done because cardiac radiation doses in women given radiotherapy for left-sided tumors are
usually larger than the cardiac radiation doses in women with right-sided tumors, and breast
cancer laterality has, in the past, played little part in determining who should be given
radiotherapy.
As shown in Fig. 5, for breast cancer patients who were not treated with radiotherapy, the
subsequent risk of heart disease was independent of tumor laterality, while for irradiated
patients, the heart disease mortality ratio, left-sided vs. right-sided tumors, increased with
increasing time since diagnosis (i.e., with increasing time since irradiation). The increase
was specific to heart disease as, for mortality from all other known causes, the left-sided vs.
right-sided mortality ratio was close to unity in both irradiated and unirradiated patients.
That suggests that the increasing trend in the left-sided vs. right-sided mortality ratio for
heart disease shown in Fig. 5 is caused by radiotherapy, with the bulk of the risk occurring
more than a decade after exposure. The proportional increase was higher for women
irradiated at ages 20 to 49 than at older ages, but the trend did not reach statistical
significance.
A recent study examining the incidence of CAD following breast irradiation (40) revealed a
higher prevalence of stress test abnormalities in left-sided than in right-sided tumor patients
(59% vs. 8%; p = 0.001). Among left-sided tumor patients, the disease distribution differed
from that expected in women, with a preponderance of left anterior descending artery
disease. The anterior portion of the heart and the left anterior descending artery territory are
the parts of the heart most often within the tangential radiation fields used to treat breast
cancer. Hence, this finding provides direct evidence of a causal effect of radiotherapy on the
development of CAD.
Imaging Studies
The long latency between radiation exposure and development of symptomatic RRHD
prevents a direct assessment of the cardiovascular risks of current or planned radiotherapy
regimens within a practical time scale. Therefore, early surrogate endpoints predictive of the
development of later cardiac events would be useful.
Nuclear medicine imaging can assess quantitatively acute and early chronic myocardial
perfusion changes and functional deficits due to ischemic heart disease (41). Marks et al.
(42) initiated a prospective study to assess changes in myocardial perfusion and function
following tangential photon irradiation of left-sided breast cancer. Patients underwent
preradiotherapy and serial 6-month postradiotherapy cardiac single-photon emission
computed tomography (SPECT) scans. The frequency of perfusion defects was related to the
percentage of the left ventricle within the tangential photon fields. Wall motion
abnormalities were more common in patients with perfusion abnormalities than in those
without. Typically, perfusion defects and the associated wall motion abnormality were in the
anterior wall of the left ventricle, corresponding to the region of the heart within the
radiotherapy field (Fig. 6).
Repeat scanning at 3 to 8 years after radiotherapy of patients with abnormalities at earlier
time points demonstrated that perfusion defects persisted (43). Such defects have been
associated with modest wall motion abnormalities but at present have not been shown to be
predictive of clinical cardiac events such as congestive heart failure or MI. Thus, their
clinical significance remains unproven. Nevertheless, as patients irradiated in the past for
left-sided breast cancer have been shown to be at increased risk of cardiac events at more
than 10 years after breast radiotherapy (39), it is tempting to hypothesize that these perfusion
defects are related in some way to the longer-term clinical manifestations.
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Since the perfusion abnormalities follow the contour of the radiation treatment field rather
than the territorial distribution of coronary arteries, they are likely to represent a radiation-
related microvascular injury to the myocardial capillary network. That, if true, would
perhaps increase the likelihood or severity of a subsequent ischemic event. One would
hypothesize that a later MI in such an irradiated patient may produce a larger perfusion
defect and clinical consequence than would have been expected based on the location and
severity of their coronary artery lesion due to a reduction in vascular reserve (Fig. 4).
Studies of Atomic Bomb Survivors
Mortality from heart disease has been studied among atomic bomb survivors in the
Hiroshima-Nagasaki Life Span Study (LSS) for over 55 years (44). Distinctive features of
the LSS are a population of >86,000 survivors who received whole-body uniform doses;
individual radiation doses; a dose range of 0 to ~4 Gy; and complete mortality ascertainment
and cause-of-death information.
Dose-related increases in heart disease mortality in the LSS occur in both genders, based on
>8,400 heart disease deaths. The risk increased by 14% per Gy (95% CI, 6–23%), although
it is not certain that there was any increase below about 0.5 Gy (44). It is unclear when the
increase started, as there were substantial healthy survivor selection effects for at least a
decade. However, even 50 years after irradiation, there is no suggestion that the risk has
diminished.
The 14% increase in risk per Gy seen in the LSS is larger than the 3% per Gy seen in
women in randomized trials of breast cancer patients. Confounding is unlikely to be
responsible for the difference, as controlling for smoking, alcohol consumption, diabetes,
obesity, education, and occupation had almost no effect on the estimates in the LSS. Also,
the Adult Health Study biennial examinations of a subset of atomic bomb survivors provide
additional support for an effect of radiation on heart disease in this population through
associations of radiation exposure with alterations in blood pressure (45) and preclinical
cardiovascular disease effects, including inflammatory markers (46) and lipid metabolism
(47). The nominal difference in risk per Gy may be due to the fact that irradiation of the
breast cancer patients is fractionated (2). Other possible reasons include Japanese/Western
baseline differences in heart disease mortality rates, differences in age at exposure, and
substantially less homogeneous cardiac radiation doses during breast cancer radiotherapy.
Occupational Studies
Radiologists and radiologic technologists undoubtedly received substantial fractionated
radiation doses in the early years. Although individual dose estimates are not available,
several studies have subdivided them by year of registration to groups likely to have
received different doses 48, 49 and 50. In the United Kingdom, cancer mortality was higher
in radiologists than in other medical practitioners for those registered during 1897 to 1920,
suggesting a radiation-related excess (RR = 1.75; 95% CI, 1.34–2.26), and mortality
declined significantly with the increasing year of registration, as would be expected from the
declining doses over the 20th Century. In contrast, mortality from circulatory disease for
those registered during 1897 to 1921 was lower in radiologists than in other medical
practitioners (RR = 0.79; 95% CI, 0.66–0.94), and there was no suggestion of any trend with
year of registration. Those data appear incompatible with a substantial radiation-related
excess of circulatory disease in the early group. However, a study of 90,000 US radiologic
technologists found increased risks of circulatory disease in those starting work prior to
1940 compared with those starting after 1960 (RR = 1.42; 95% CI, 1.04–1.94). This increase
was mostly due to cerebrovascular disease (RR = 2.40; 95% CI, 1.09–5.31), rather than
ischemic heart disease (RR = 1.22; 95% CI, 0.81–1.82) (50).
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There are major gaps in current knowledge of the structures at risk and mechanisms of
damage in RRHD. It is uncertain whether there is a threshold dose of radiation to the heart
below which no risk is incurred. Even at doses sufficient to increase risk, estimates of its
magnitude for a given cardiac dose are still subject to considerable uncertainty, and
knowledge about the shape of the dose-response relationship and factors that modify it is
rudimentary, both for heart disease as a whole and for specific heart diseases. There are
substantial dose inhomogeneities within the heart during radiation therapy, but it is not
known which part of the heart is the most radiosensitive, nor which structure or structures at
risk should be chosen as a reference point for tolerance doses in clinical practice. Additional
important gaps in current knowledge include the relationship between short-term effects and
long-term risk and the extent to which cardiac risk may be modified by other factors such as
irradiation of other organs (e.g., kidneys), preexisting cardiovascular disease or diabetes,
lifestyle factors including smoking, and interactions with cardiotoxic drugs used in
combination with radiotherapy during cancer treatment.
Experimental models
Experimental models offer the greatest scope for increasing understanding of the cellular
and molecular mechanisms of RRHD. A project utilizing high-precision cardiac irradiation
of established murine models with prolonged follow-up, in combination with ex vivo and in
vitro techniques, is presently underway (51). That project should eventually shed light on
whether radiation operates predominantly by accelerating age-related coronary artery
atherosclerosis by reducing the heart’s tolerance to acute infarctions through microvascular
damage to the myocardium, or whether both mechanisms are important.
Other topics that may be amenable to study experimentally include the sensitivities of
specific cardiac substructures and the effect of irradiation of organs such as the kidney on
risk of heart disease. Experimental models may also shed light on possible intervention
strategies to reduce the risk in patients receiving radiotherapy, although the possibility of
appreciable interspecies differences complicates the immediate application of promising
findings to humans.
Scientific studies of exposed individuals
Further insight into the way in which the risk of death from RRHD varies with time since
exposure and age is expected soon from a multinational study of cause-specific mortality
after left-sided vs. right-sided breast cancer irradiation in over 1 million women (52).
Information on cardiac morbidity and also on the possible modifying effects of preexisting
heart disease and conventional cardiovascular risk factors such as diabetes, kidney disease,
and hypertension will be available for a subset of the data 52 and 53.
In some countries it is possible to link information on the subsequent morbidity and
mortality of cancer patients with estimates of dose to the whole heart and some cardiac
substructures derived from individual radiotherapy charts (36). Although retrospective dose
estimates lack the accuracy of prospective studies due to an absence of individual three-
dimensional treatment plans, they should provide a broad dose–response relationship for
radiation-induced heart disease for doses ranging from about 1 to 20 Gy (53). They should
also provide insight into the combined cardiotoxicity of radiation and drugs, such as
anthracyclines, taxanes, or trastuzumab.
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Studies of irradiated breast cancer patients can avoid selection biases by making use of the
left-right comparison. Clearly, however, they can provide no information about the effects of
cardiac irradiation in children or in men. It may be possible to derive quantitative risk
estimates in patients with childhood cancer or from men with cancers such as HL who have
taken part in randomized trials of radiotherapy, but quantitative estimates from
nonrandomized studies need to be interpreted with caution unless it can be established that
the effects of selection are small.
Clinical studies of the atomic bomb survivors that employ a broad range of physical,
imaging, and biomarker measurements are underway. Those studies aim to evaluate
prospectively various potential mechanisms of radiation-related subclinical and clinical
cardiovascular disease.
Several studies that were initiated to study radiation-related cancer in nuclear industry
workers have large population sizes, long follow-up, and generally well-characterized doses,
mostly of <0.5 Gy. It is possible that they may eventually provide information on the risks
of RRHD. The low doses involved in such studies limit their statistical power. In addition, a
major concern is that any dose-response relationship may be subject to confounding by
smoking and other lifestyle factors. So far, little has been done to control for such factors in
those studies.
Monitoring and prevention of risk in exposed individuals
The cardiac doses delivered by contemporary radiotherapy for cancer are lower than those
delivered in previous decades (54). Cardiac risks are therefore likely to be correspondingly
lower, but in the absence of reliable dose-response relationships, the extent of any risks from
current therapies remains uncertain. The current era of three-dimensional computerized
tomography treatment planning for radiotherapy enables the dose delivered to the whole
heart and to specific cardiac substructures in any specific treatment plan to be estimated
precisely. Hence, those carrying out treatment planning may have more control over cardiac
doses than ever before. If reliable dose-response relationships for cardiac risk were
available, useful prospective treatment-planning parameters could be derived (55),
especially if the dose-response relationships also considered the impact of adjuvant systemic
therapies and patient-specific factors.
The recognition and treatment of conventional cardiovascular risk factors, such as
hypertension and hypercholesterolemia, can improve outcomes. As studies have suggested
that the presence of conventional risk factors is a major modifier in the development of
radiation-induced cardiovascular disease (20), there is an argument that those given thoracic
radiotherapy may benefit from increased surveillance of these risk factors. Thus, a first step
is to increase awareness among practicing physicians of radiation as an additional risk
factor. An American Society of Clinical Oncology (ASCO) clinical evidence review
published in 2007 (56) emphasized the absence of high-quality evidence regarding the best
methods and possible benefits of screening for late cardiac effects of cancer therapies. This
deficit in knowledge will become increasingly important as the number of long-term cancer
survivors is predicted to increase dramatically over the next decade. Further research is
required into surveillance and targeted intervention strategies, so that evidence-based
guidelines for long-term cardiac follow-up of those patients at risk can be developed.
Radiological protection
There are approximately 400 million diagnostic medical examinations performed annually
in the United States and some 3.6 billion worldwide. In addition, there are almost 4 million
workers monitored occupationally for potential radiation exposure in the United States and
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over 15 million worldwide. Present radiological protection guidelines and regulations are
concerned solely with radiation-related cancers and hereditary effects and do not consider
RRHD. Virtually all the exposure occurs at doses of below 0.5 Gy, and, at the present time,
it is unclear whether such low doses pose any cardiac risk. Therefore, it is as yet unclear
whether there will be any future need to take explicit account of RRHD in radiation
protection.
CONCLUDING REMARKS
Further knowledge about the nature and magnitude of radiation-related heart disease would
have immediate application in radiation oncology. It would also provide a basis for radiation
protection policies for use in diagnostic and occupational exposure.
To our knowledge, this review is first time that individuals from such a wide range of
disciplines, including pathology, radiobiology, cardiology, radiation oncology,
epidemiology, statistics, and diagnostic radiology have collaborated to share knowledge
about RRHD. All those different disciplines have roles to play in furthering knowledge and
in reducing the future burden of RRHD. Knowledge accumulated in one discipline may
often be published in specialized journals that are not regularly read by those working in
other disciplines, and technical terminology often impedes ready interpretation by those in
other disciplines. We therefore conclude that future multidisciplinary reviews examining the
topics raised here in greater depth and summarizing new findings are needed.
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Perpendicular sections of human pericardium. The left panel illustrates the normal parietal
pericardium with a thin, uniform fibrous layer that faces the heart (upper section) and an
outer layer of adipose tissue (lower section). The right panel is a typical example of
irradiated pericardium at 17 months after receiving 67 Gy. The adipose tissue has been
replaced by dense fibrous tissue that actually extends well below the limits of this
micrograph. Hematoxylin-eosin stain. (From Kajardo LF. The pathology of ionizing
radiation as defined by morphologic patterns. Keynote lecture. 5th Nordic Conference on
Radiation Oncology. Bergen. Norway. Acta Oncologica 2005;44:13–22. with permission.)
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Fatal diffuse myocardial fibrosis several years after irradiation for Hodgkin’s disease.
Whereas normally there should be very little collagen among the dark red myocytes, this
heart muscle is criss-crossed by multiple bands of blue collagen. Gomori trichrome stain.
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Left anterior descending coronary artery in a 16-year-old boy 1 year after receiving 40 Gy
mantle radiotherapy for Hodgkin’s disease. Myointimal proliferation has considerably
narrowed the lumen. Fatal cases like this in a patient who had no cardiac risk factors other
than radiation illustrate that the morphology of arterial disease due to radiation is essentially
no different from that of age-related atherosclerosis. Hematoxylin-eosin stain. (From
Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns.
Keynote lecture. 5th Nordic Conference on Radiation Oncology, Bergen. Norway. Acta
Oncologica 2005;44:13–22; with permission.)
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An outline of how microvascular and macrovascular radiation-related cardiac injury could
theoretically combine to cause myocardial ischemia after RT.
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Left-sided vs. right-sided breast cancer. Mortality ratios by radiotherapy status, cause, and
years since diagnosis in 300,000 women with breast cancer and registered in the
Surveillance Epidemiology and End Results (SEER) cancer registries, 1973 to 2001 (From
Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung
cancer after radiotherapy for early breast cancer: Prospective study of about 300,000 women
in US SEER cancel registries. Lancet Oncol 2005;6:557–565: with permission.)
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Representative axial images pre-RT (left panel) and post-RT (right panel) cardiac SPECT
scans. The deep borders of the tangential RT beams are shown as solid lines. A new
perfusion defect in the anterior left ventricle after radiation is seen.
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